

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants:** Gessica Filocamo *et al.*

**Serial No.:** 10/586,701

Case No.: ITR0064YP

**Filed:** July 20, 2006

**For:** INHIBITORS OF MAMMALIAN HDAC11 USEFUL  
FOR TREATING HDAC 11 MEDIATED DISORDERS

**Art Unit:**  
To be assigned

**Examiner:**  
To be assigned

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

Dear Sirs:

In response to the Notification of Defective Response mailed May 27, 2009, for which a response is due by June 27, 2009, and in compliance with 37 C.F.R. 1.821(f) of the Rules of Practice in Patent Cases: Application Disclosures Containing Nucleotide And/Or Amino Acid Sequences, the signature page and following statements are being submitted herewith.

The sequence listing of the present invention is being submitted electronically via EFS-Web as an ASCII formatted sequence listing with a file name ITR0064YP-SEQTXT-16JUN2009", creation date 06/16/2009, and a size of 8,837 bytes. Also submitted is a new paper copy sequence listing labeled "ITR0064YP-SEQLIST-16JUN2009".

Applicants believe no additional fees are due but the Commissioner is authorized to charge any fees in connection with this response to Merck Deposit Account No. 13-2755.

Respectfully submitted,

By /Vineet Kohli, Reg. No. 37003 /  
Vineet Kohli  
Registration No. 37,003  
Attorney for Applicants

Merck & Co., Inc.  
PO Box 2000 - RY 60-30  
Rahway, New Jersey 07065-0907  
Telephone No. (732) 594-3889

Date: June 16, 2009